ReviewNature reviews. Nephrology2009
ANCA-associated vasculitis: from bench research to novel treatments.
Review in Nature reviews. Nephrology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 21 citations in OpenAlex.
- ANCA-associated small vessel vasculitis: clinical and therapeutic advances.Current rheumatology reports · 2010Review
- Management of ANCA-associated vasculitis: Current trends and future prospects.Therapeutics and clinical risk management · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Small-vessel vasculitic syndromes such as Wegener granulomatosis and microscopic polyangiitis, which are associated with circulating antineutrophil cytoplasmic autoantibodies, are an important cause of renal failure. Current immunosuppressive regimens based on cyclophosphamide have significantly improved survival in patients with these conditions. However, such treatments are toxic, increase the risk of infection and do not cure the disease; fresh approaches are, therefore, required. An increased understanding of the pathogenesis of these syndromes has allowed the rational use of newer therapies such as rituximab, an anti-CD20 chimeric monoclonal antibody that depletes B cells. Further understanding of the disease pathogenesis is crucial to the development of novel targeted therapies, which are urgently required to improve patient prognosis. Future potential therapies include molecules that block signaling pathways that are essential in the pathogenesis of these diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.